CPS1 deficiency is a dubious disease in the field of genetic metabolism, clinical performance is complex and often involves multi-systematic fatigue. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of CPS1 requires a comprehensive assessment platform such as clinical performance, imaging, laboratory testing and pathological activation.
A team of authoritative experts at home and abroad can assist in providing accurate diagnosis and treatment. Treatment and management of CPS1 deficiencies require individual treatment plans, usually including drug treatment, rehabilitation interventions, and regular follow-up dimension management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat genetic metabolic disorders have been significantly improved.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapted to timely regimes according to changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the lack of CPS1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.